Mesoblast MESO releases its next round of earnings Wednesday. Here's Benzinga's essential guide to Mesoblast's Q4 earnings report.
Earnings and Revenue
Analysts are predicting Mesoblast will report a loss of 23 cents per share on revenue of $2.89 million.
In the same quarter last year, Mesoblast announced an EPS loss of 6 cents on revenue of $566,000. Revenue would be up 410.6 percent from the year-ago period. Mesoblast's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
| EPS Estimate | -0.22 | -0.21 | -0.25 | -0.23 |
| EPS Actual | -0.045 | -0.02 | -0.02 | -0.06 |
Stock Performance
Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Long-term shareholders are already wary of 12-month losses prior to the announcement.
Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. Analysts have been rating Mesoblast stock as Sell. The strength of this rating has dwindled over the past three months.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
